Comparing two methods for relieving cancer pain
Comparing the Effects of Coeliac Plexus Neurolysis Versus Splanchnic Nerve Neurolysis for Non-pancreatic Upper Intra-abdominal Cancer Pain: a Prospective Randomized Study
This study is testing which pain relief method, coeliac plexus neurolysis or splanchnic nerve neurolysis, works better for patients with hard-to-treat abdominal cancers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05541211 on ClinicalTrials.gov |
What this trial studies
This study compares the effectiveness of coeliac plexus neurolysis (CPN) and splanchnic nerve neurolysis (SNN) in managing pain for patients with unresectable intra-abdominal cancers. While CPN has been established as effective for pancreatic cancer pain, the efficacy of SNN for other types of abdominal cancer pain is being explored. Participants will be assessed for their pain levels and ability to tolerate the procedures, with the aim of determining which method provides better pain relief. The study focuses on patients who experience significant visceral pain due to their cancer.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with unresectable intra-abdominal cancer and significant visceral pain.
Not a fit: Patients with primary pancreatic cancer or those who have had previous neurolytic procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective pain management option for patients with various types of abdominal cancer.
How similar studies have performed: Previous studies have shown success with coeliac plexus neurolysis for pancreatic cancer, but the efficacy of splanchnic nerve neurolysis for other abdominal cancers is less established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age\>=18 * Diagnosis of unresectable intra-abdominal cancer * Visceral pain attributable to the cancer with NRS \>= 4 * Able to understand instructions, give consent, complete questionnaires Exclusion Criteria: * Primary pancreatic cancer or metastatic disease involving pancreas * Gross celiac axis distortion identified on imaging * Acute abdomen condition eg. Intraabdominal sepsis, tumor rupture * Other non-cancer causes attributable to the pain * Gross ascites * Previous coeliac plexus or splanchnic nerve neurolysis * Contraindications to neurolytic procedures eg. Bleeding tendency; local or systemic infections; allergic to local anesthetics, contrast or alcohol; intestinal obstruction; anatomical distortion along needle trajectory * Patients believed to be inappropriate for study by investigators
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Timmy CW Chan, MBBS
- Email: timmychancw@gmail.com
- Phone: 22555791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.